The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy, maximal tolerated dose, and toxicokinetics of TTC-352 in rats and dogs, a partial ER agonist for metastatic ER+ breast cancer.
 
Debra A. Tonetti
Leadership - TTC Oncology
Stock and Other Ownership Interests - TTC Oncology
Consulting or Advisory Role - TTC Oncology
Patents, Royalties, Other Intellectual Property - G1 Therapeutics; G1 Therapeutics (Inst); TTC Oncology; TTC Oncology (Inst)
 
Rui Xiong
Patents, Royalties, Other Intellectual Property - G1 Therapeutics; G1 Therapeutics (Inst); TTC Oncology; TTC Oncology (Inst)
 
Jiong Zhao
Patents, Royalties, Other Intellectual Property - G1 Therapeutics; G1 Therapeutics (Inst)
 
Lauren Gutgesell
No Relationships to Disclose
 
Arkadiusz Z. Dudek
Employment - Adhaere Pharmaceuticals
Leadership - IGF Oncology; Martell diagnostic
Stock and Other Ownership Interests - Adhaere Pharmaceuticals; Biothera; IGF Oncology; Vanquish Oncology
Honoraria - Biothera; IGF Oncology; Medtronic; Vanquish Oncology
Consulting or Advisory Role - Biothera; TTC Oncology; Vanquish Oncology
 
Gregory R. Thatcher
Leadership - TTC Oncology
Stock and Other Ownership Interests - TTC Oncology
Consulting or Advisory Role - TTC Oncology
Patents, Royalties, Other Intellectual Property - G1 Therapeutics; G1 Therapeutics (Inst); TTC Oncology; TTC Oncology (Inst)